While weight-loss drugs like Zepbound (LLY) and Wegovy (NVO) offer significant health benefits, their high costs make them ...

A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical ...

As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...

Emerging evidence shows glucose-lowering medications may have the potential to improve chronic obstructive pulmonary disease ...

M illions of Americans have tried GLP-1 medications like Ozempic, Mounjaro and Wegovy, polls show, but pharmacy claims data ...

The new $5.3 billion deal with the Swiss pharma giant gives Zealand a significant partner to advance its amylin analog obesity shot and create a new combination product.

The once-daily pill combines Opko’s long-acting GLP-1/glucagon dual agonist peptide, dubbed OPK-88006, with Entera’s N-Tab ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

Tirzepatide and semaglutide were associated with larger QALY gains (incremental gains of 0.35 and 0.25 over lifestyle ...

“Whether consumers are using GLP-1 medications for weight management or are reducing sugar intake as part of their overall ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

As it gets harder to offer compounded GLP-1s, many telehealth companies are pivoting to hormone replacement therapy.